vs

Side-by-side financial comparison of Excelerate Energy, Inc. (EE) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Excelerate Energy, Inc. is the larger business by last-quarter revenue ($317.6M vs $207.3M, roughly 1.5× Ultragenyx Pharmaceutical Inc.). On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 15.7%). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 26.0%).

Excelerate Energy, Inc. is a global leading provider of flexible liquefied natural gas (LNG) solutions, offering floating storage and regasification units, LNG delivery services and integrated infrastructure projects. It serves utility and industrial clients across Europe, Asia, Latin America and the Middle East, supporting markets to achieve accessible low-carbon energy transitions.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

EE vs RARE — Head-to-Head

Bigger by revenue
EE
EE
1.5× larger
EE
$317.6M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+10.2% gap
RARE
25.9%
15.7%
EE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
26.0%
EE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EE
EE
RARE
RARE
Revenue
$317.6M
$207.3M
Net Profit
$-128.6M
Gross Margin
Operating Margin
22.2%
-54.7%
Net Margin
-62.0%
Revenue YoY
15.7%
25.9%
Net Profit YoY
3.5%
EPS (diluted)
$0.24
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EE
EE
RARE
RARE
Q4 25
$317.6M
$207.3M
Q3 25
$391.0M
$159.9M
Q2 25
$204.6M
$166.5M
Q1 25
$315.1M
$139.3M
Q4 24
$274.6M
$164.6M
Q3 24
$193.4M
$139.5M
Q2 24
$183.3M
$147.0M
Q1 24
$200.1M
$108.8M
Net Profit
EE
EE
RARE
RARE
Q4 25
$-128.6M
Q3 25
$-180.4M
Q2 25
$-115.0M
Q1 25
$-151.1M
Q4 24
$-133.2M
Q3 24
$-133.5M
Q2 24
$-131.6M
Q1 24
$-170.7M
Operating Margin
EE
EE
RARE
RARE
Q4 25
22.2%
-54.7%
Q3 25
22.3%
-106.9%
Q2 25
21.2%
-64.8%
Q1 25
20.9%
-102.6%
Q4 24
21.9%
-74.3%
Q3 24
30.9%
-94.6%
Q2 24
27.2%
-79.1%
Q1 24
22.6%
-151.9%
Net Margin
EE
EE
RARE
RARE
Q4 25
-62.0%
Q3 25
-112.8%
Q2 25
-69.0%
Q1 25
-108.5%
Q4 24
-80.9%
Q3 24
-95.7%
Q2 24
-89.5%
Q1 24
-156.8%
EPS (diluted)
EE
EE
RARE
RARE
Q4 25
$0.24
$-1.28
Q3 25
$0.43
$-1.81
Q2 25
$0.15
$-1.17
Q1 25
$0.46
$-1.57
Q4 24
$0.42
$-1.34
Q3 24
$0.35
$-1.40
Q2 24
$0.26
$-1.52
Q1 24
$0.24
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EE
EE
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$538.2M
$421.0M
Total DebtLower is stronger
$936.3M
Stockholders' EquityBook value
$2.2B
$-80.0M
Total Assets
$4.1B
$1.5B
Debt / EquityLower = less leverage
0.42×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EE
EE
RARE
RARE
Q4 25
$538.2M
$421.0M
Q3 25
$462.6M
$202.5M
Q2 25
$426.0M
$176.3M
Q1 25
$619.5M
$127.1M
Q4 24
$537.5M
$174.0M
Q3 24
$608.4M
$150.6M
Q2 24
$609.1M
$480.7M
Q1 24
$578.9M
$112.3M
Total Debt
EE
EE
RARE
RARE
Q4 25
$936.3M
Q3 25
$942.0M
Q2 25
$946.2M
Q1 25
$322.6M
Q4 24
$333.6M
Q3 24
$345.7M
Q2 24
$356.4M
Q1 24
$366.9M
Stockholders' Equity
EE
EE
RARE
RARE
Q4 25
$2.2B
$-80.0M
Q3 25
$2.2B
$9.2M
Q2 25
$2.1B
$151.3M
Q1 25
$1.9B
$144.2M
Q4 24
$1.9B
$255.0M
Q3 24
$1.9B
$346.8M
Q2 24
$1.8B
$432.4M
Q1 24
$1.8B
$140.3M
Total Assets
EE
EE
RARE
RARE
Q4 25
$4.1B
$1.5B
Q3 25
$4.1B
$1.2B
Q2 25
$4.0B
$1.3B
Q1 25
$2.9B
$1.3B
Q4 24
$2.9B
$1.5B
Q3 24
$2.9B
$1.5B
Q2 24
$2.9B
$1.6B
Q1 24
$2.9B
$1.3B
Debt / Equity
EE
EE
RARE
RARE
Q4 25
0.42×
Q3 25
0.43×
Q2 25
0.44×
Q1 25
0.17×
Q4 24
0.18×
Q3 24
0.18×
Q2 24
0.19×
Q1 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EE
EE
RARE
RARE
Operating Cash FlowLast quarter
$104.4M
$-99.8M
Free Cash FlowOCF − Capex
$-100.8M
FCF MarginFCF / Revenue
-48.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EE
EE
RARE
RARE
Q4 25
$104.4M
$-99.8M
Q3 25
$114.9M
$-91.4M
Q2 25
$87.1M
$-108.3M
Q1 25
$154.8M
$-166.5M
Q4 24
$49.6M
$-79.3M
Q3 24
$39.8M
$-67.0M
Q2 24
$90.4M
$-77.0M
Q1 24
$64.7M
$-190.7M
Free Cash Flow
EE
EE
RARE
RARE
Q4 25
$-100.8M
Q3 25
$-92.7M
Q2 25
$-110.7M
Q1 25
$-167.8M
Q4 24
$-79.5M
Q3 24
$-68.6M
Q2 24
$-79.0M
Q1 24
$-193.9M
FCF Margin
EE
EE
RARE
RARE
Q4 25
-48.6%
Q3 25
-58.0%
Q2 25
-66.5%
Q1 25
-120.5%
Q4 24
-48.3%
Q3 24
-49.2%
Q2 24
-53.7%
Q1 24
-178.2%
Capex Intensity
EE
EE
RARE
RARE
Q4 25
0.5%
Q3 25
0.8%
Q2 25
1.5%
Q1 25
1.0%
Q4 24
0.1%
Q3 24
1.2%
Q2 24
1.4%
Q1 24
3.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EE
EE

Other$179.4M57%
Revenue From Leases$138.1M43%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons